Tiludronate concentrations and cytologic findings in synovial fluid after intravenous regional limb perfusion with tiludronate in horses

Anecdotal accounts of tiludronate administration via intravenous regional limb perfusion (IVRLP) exist despite a lack of information regarding safety for synovial structures in the perfused area. The objective of this study was to determine whether tiludronate concentrations in synovial structures a...

Full description

Saved in:
Bibliographic Details
Published in:PeerJ (San Francisco, CA) CA), 2015-04, Vol.3, p.e889-e889
Main Authors: Hunter, Barbara G, Duesterdieck-Zellmer, Katja F, Larson, Maureen K
Format: Article
Language:English
Subjects:
Analysis
Arthritis
Bone disorder agents
Cartilage (articular)
Cellular biology
Cytology
Data processing
Disease
Drugs and Devices
Horse
Horses
Intravenous administration
Intravenous regional limb perfusion
Limbs
Orthopedics
Perfusion
Pharmacology
Synovial fluid
Tiludronate
Veins & arteries
Veterinary Medicine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c637t-ee94f2a5906156ce884c3e4b9bcf24ab437a2a6264f70aca37f9f268952f9dbb3
cites cdi_FETCH-LOGICAL-c637t-ee94f2a5906156ce884c3e4b9bcf24ab437a2a6264f70aca37f9f268952f9dbb3
container_end_page e889
container_issue
container_start_page e889
container_title PeerJ (San Francisco, CA)
container_volume 3
creator Hunter, Barbara G
Duesterdieck-Zellmer, Katja F
Larson, Maureen K
description Anecdotal accounts of tiludronate administration via intravenous regional limb perfusion (IVRLP) exist despite a lack of information regarding safety for synovial structures in the perfused area. The objective of this study was to determine whether tiludronate concentrations in synovial structures after IVRLP with low dose (0.5 mg, LDT) or high dose (50 mg, HDT) tiludronate remain below a value demonstrated in vitro to be safe for articular cartilage (19,000 ng/ml in DIP joints of two HDT limbs. Tiludronate was measurable only in synovial fluid from HDT limbs 24 h post-perfusion. There were no differences in synovial fluid cytology variables between control and treated limbs. Conclusions. In some horses, IVRLP with HDT may result in synovial fluid concentrations of tiludronate that may have adverse effects on articular cartilage, based on in vitro data. IVRLP with LDT is unlikely to promote articular cartilage degradation. Further studies to determine a safe and effective dose for IVRLP with tiludronate are needed.
doi_str_mv 10.7717/peerj.889
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_2d5a564c70e5490eab5d7588cd51a00b</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A543478006</galeid><doaj_id>oai_doaj_org_article_2d5a564c70e5490eab5d7588cd51a00b</doaj_id><sourcerecordid>A543478006</sourcerecordid><originalsourceid>FETCH-LOGICAL-c637t-ee94f2a5906156ce884c3e4b9bcf24ab437a2a6264f70aca37f9f268952f9dbb3</originalsourceid><addsrcrecordid>eNptks1qGzEUhYfS0oQ0i75AERRKu3CqGf1vCiH0JxDoJl0LjebKlpElV5px8Bv0sSvbaWqXSguJq-8eoaPTNK9bfCVEKz6uAfLySkr1rDnvWi5mkjD1_Gh_1lyWssR1yI5jSV42Zx1TlBFMzptf9z5MQ07RjIBsihbimM3oUyzIxAHZ7ZhCmnuLnI-Dj_OCfERlG9PGm4BcmPyAjBsh13rt3EBMU0EZ5lWiAsGverSG7KZSC-jBjws0Hl1ZxRYpFyivmhfOhAKXj-tF8-PL5_ubb7O7719vb67vZpYTMc4AFHWdYQrzlnELUlJLgPaqt66jpqdEmM7wjlMnsLGGCKdcx6VinVND35OL5vagOySz1OvsVyZvdTJe7wspz7XJo7cBdDcwwzi1AgOjCoPp2SCYlHZgrcF4p_XpoLWe-hUMB-_CiejpSfQLPU8bTWmrKMVV4P2jQE4_JyijXvliIQQTodqoWy5xK2nHeEXf_oMu05SrxZVSTHDC6-_-peamPsBHl-q9dieqrxklVEiMd9TVf6g6B1j5GgJwvtZPGt4dNSzAhHFRUpj2OTkFPxxAm1MpGdyTGS3Wu7jqfVx1jWtl3xy790T-CSf5DVQf6Ds</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1957636826</pqid></control><display><type>article</type><title>Tiludronate concentrations and cytologic findings in synovial fluid after intravenous regional limb perfusion with tiludronate in horses</title><source>Open Access: PubMed Central</source><source>Publicly Available Content (ProQuest)</source><creator>Hunter, Barbara G ; Duesterdieck-Zellmer, Katja F ; Larson, Maureen K</creator><creatorcontrib>Hunter, Barbara G ; Duesterdieck-Zellmer, Katja F ; Larson, Maureen K</creatorcontrib><description>Anecdotal accounts of tiludronate administration via intravenous regional limb perfusion (IVRLP) exist despite a lack of information regarding safety for synovial structures in the perfused area. The objective of this study was to determine whether tiludronate concentrations in synovial structures after IVRLP with low dose (0.5 mg, LDT) or high dose (50 mg, HDT) tiludronate remain below a value demonstrated in vitro to be safe for articular cartilage (&lt;19,000 ng/ml), and to determine effects of tiludronate on synovial fluid cytology variables compared to saline perfused control limbs. Using a randomized controlled experimental study design, horses received IVRLP with LDT (n = 6) or HDT (n = 6) in one forelimb and IVRLP with saline in the contralateral limb. Synovial fluid cytology variables and tiludronate concentrations were evaluated in navicular bursae (NB), and distal interphalangeal (DIP) and metacarpophalangeal (MCP) joints one week before and 30-45 min after IVRLP, and in DIP and MCP joints 24 h after IVRLP. Data were analyzed with 2-way rmANOVA (p &lt; 0.05). Highest measured synovial fluid tiludronate concentrations occurred 30-45 min post-perfusion. Mean tiludronate concentrations were lower in LDT limbs (MCP = 39.6 ± 14.3 ng/ml, DIP = 118.1 ± 66.6 ng/ml, NB = 82.1 ± 30.2 ng/ml) than in HDT limbs (MCP = 3,745.1 ± 1,536.6 ng/ml, DIP = 16,274.0 ± 5,460.2 ng/ml, NB = 6,049.3 ± 1,931.7 ng/ml). Tiludronate concentration was &gt;19,000 ng/ml in DIP joints of two HDT limbs. Tiludronate was measurable only in synovial fluid from HDT limbs 24 h post-perfusion. There were no differences in synovial fluid cytology variables between control and treated limbs. Conclusions. In some horses, IVRLP with HDT may result in synovial fluid concentrations of tiludronate that may have adverse effects on articular cartilage, based on in vitro data. IVRLP with LDT is unlikely to promote articular cartilage degradation. Further studies to determine a safe and effective dose for IVRLP with tiludronate are needed.</description><identifier>ISSN: 2167-8359</identifier><identifier>EISSN: 2167-8359</identifier><identifier>DOI: 10.7717/peerj.889</identifier><identifier>PMID: 25945303</identifier><language>eng</language><publisher>United States: PeerJ. Ltd</publisher><subject>Analysis ; Arthritis ; Bone disorder agents ; Cartilage (articular) ; Cellular biology ; Cytology ; Data processing ; Disease ; Drugs and Devices ; Horse ; Horses ; Intravenous administration ; Intravenous regional limb perfusion ; Limbs ; Orthopedics ; Perfusion ; Pharmacology ; Synovial fluid ; Tiludronate ; Veins &amp; arteries ; Veterinary Medicine</subject><ispartof>PeerJ (San Francisco, CA), 2015-04, Vol.3, p.e889-e889</ispartof><rights>COPYRIGHT 2015 PeerJ. Ltd.</rights><rights>2015 Hunter et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2015 Hunter et al. 2015 Hunter et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c637t-ee94f2a5906156ce884c3e4b9bcf24ab437a2a6264f70aca37f9f268952f9dbb3</citedby><cites>FETCH-LOGICAL-c637t-ee94f2a5906156ce884c3e4b9bcf24ab437a2a6264f70aca37f9f268952f9dbb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1957636826/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1957636826?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25752,27923,27924,37011,37012,44589,53790,53792,74897</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25945303$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hunter, Barbara G</creatorcontrib><creatorcontrib>Duesterdieck-Zellmer, Katja F</creatorcontrib><creatorcontrib>Larson, Maureen K</creatorcontrib><title>Tiludronate concentrations and cytologic findings in synovial fluid after intravenous regional limb perfusion with tiludronate in horses</title><title>PeerJ (San Francisco, CA)</title><addtitle>PeerJ</addtitle><description>Anecdotal accounts of tiludronate administration via intravenous regional limb perfusion (IVRLP) exist despite a lack of information regarding safety for synovial structures in the perfused area. The objective of this study was to determine whether tiludronate concentrations in synovial structures after IVRLP with low dose (0.5 mg, LDT) or high dose (50 mg, HDT) tiludronate remain below a value demonstrated in vitro to be safe for articular cartilage (&lt;19,000 ng/ml), and to determine effects of tiludronate on synovial fluid cytology variables compared to saline perfused control limbs. Using a randomized controlled experimental study design, horses received IVRLP with LDT (n = 6) or HDT (n = 6) in one forelimb and IVRLP with saline in the contralateral limb. Synovial fluid cytology variables and tiludronate concentrations were evaluated in navicular bursae (NB), and distal interphalangeal (DIP) and metacarpophalangeal (MCP) joints one week before and 30-45 min after IVRLP, and in DIP and MCP joints 24 h after IVRLP. Data were analyzed with 2-way rmANOVA (p &lt; 0.05). Highest measured synovial fluid tiludronate concentrations occurred 30-45 min post-perfusion. Mean tiludronate concentrations were lower in LDT limbs (MCP = 39.6 ± 14.3 ng/ml, DIP = 118.1 ± 66.6 ng/ml, NB = 82.1 ± 30.2 ng/ml) than in HDT limbs (MCP = 3,745.1 ± 1,536.6 ng/ml, DIP = 16,274.0 ± 5,460.2 ng/ml, NB = 6,049.3 ± 1,931.7 ng/ml). Tiludronate concentration was &gt;19,000 ng/ml in DIP joints of two HDT limbs. Tiludronate was measurable only in synovial fluid from HDT limbs 24 h post-perfusion. There were no differences in synovial fluid cytology variables between control and treated limbs. Conclusions. In some horses, IVRLP with HDT may result in synovial fluid concentrations of tiludronate that may have adverse effects on articular cartilage, based on in vitro data. IVRLP with LDT is unlikely to promote articular cartilage degradation. Further studies to determine a safe and effective dose for IVRLP with tiludronate are needed.</description><subject>Analysis</subject><subject>Arthritis</subject><subject>Bone disorder agents</subject><subject>Cartilage (articular)</subject><subject>Cellular biology</subject><subject>Cytology</subject><subject>Data processing</subject><subject>Disease</subject><subject>Drugs and Devices</subject><subject>Horse</subject><subject>Horses</subject><subject>Intravenous administration</subject><subject>Intravenous regional limb perfusion</subject><subject>Limbs</subject><subject>Orthopedics</subject><subject>Perfusion</subject><subject>Pharmacology</subject><subject>Synovial fluid</subject><subject>Tiludronate</subject><subject>Veins &amp; arteries</subject><subject>Veterinary Medicine</subject><issn>2167-8359</issn><issn>2167-8359</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptks1qGzEUhYfS0oQ0i75AERRKu3CqGf1vCiH0JxDoJl0LjebKlpElV5px8Bv0sSvbaWqXSguJq-8eoaPTNK9bfCVEKz6uAfLySkr1rDnvWi5mkjD1_Gh_1lyWssR1yI5jSV42Zx1TlBFMzptf9z5MQ07RjIBsihbimM3oUyzIxAHZ7ZhCmnuLnI-Dj_OCfERlG9PGm4BcmPyAjBsh13rt3EBMU0EZ5lWiAsGverSG7KZSC-jBjws0Hl1ZxRYpFyivmhfOhAKXj-tF8-PL5_ubb7O7719vb67vZpYTMc4AFHWdYQrzlnELUlJLgPaqt66jpqdEmM7wjlMnsLGGCKdcx6VinVND35OL5vagOySz1OvsVyZvdTJe7wspz7XJo7cBdDcwwzi1AgOjCoPp2SCYlHZgrcF4p_XpoLWe-hUMB-_CiejpSfQLPU8bTWmrKMVV4P2jQE4_JyijXvliIQQTodqoWy5xK2nHeEXf_oMu05SrxZVSTHDC6-_-peamPsBHl-q9dieqrxklVEiMd9TVf6g6B1j5GgJwvtZPGt4dNSzAhHFRUpj2OTkFPxxAm1MpGdyTGS3Wu7jqfVx1jWtl3xy790T-CSf5DVQf6Ds</recordid><startdate>20150428</startdate><enddate>20150428</enddate><creator>Hunter, Barbara G</creator><creator>Duesterdieck-Zellmer, Katja F</creator><creator>Larson, Maureen K</creator><general>PeerJ. Ltd</general><general>PeerJ, Inc</general><general>PeerJ Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7XB</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20150428</creationdate><title>Tiludronate concentrations and cytologic findings in synovial fluid after intravenous regional limb perfusion with tiludronate in horses</title><author>Hunter, Barbara G ; Duesterdieck-Zellmer, Katja F ; Larson, Maureen K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c637t-ee94f2a5906156ce884c3e4b9bcf24ab437a2a6264f70aca37f9f268952f9dbb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Analysis</topic><topic>Arthritis</topic><topic>Bone disorder agents</topic><topic>Cartilage (articular)</topic><topic>Cellular biology</topic><topic>Cytology</topic><topic>Data processing</topic><topic>Disease</topic><topic>Drugs and Devices</topic><topic>Horse</topic><topic>Horses</topic><topic>Intravenous administration</topic><topic>Intravenous regional limb perfusion</topic><topic>Limbs</topic><topic>Orthopedics</topic><topic>Perfusion</topic><topic>Pharmacology</topic><topic>Synovial fluid</topic><topic>Tiludronate</topic><topic>Veins &amp; arteries</topic><topic>Veterinary Medicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hunter, Barbara G</creatorcontrib><creatorcontrib>Duesterdieck-Zellmer, Katja F</creatorcontrib><creatorcontrib>Larson, Maureen K</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Biological Science Collection</collection><collection>ProQuest Science Journals</collection><collection>Biological Science Database</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PeerJ (San Francisco, CA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hunter, Barbara G</au><au>Duesterdieck-Zellmer, Katja F</au><au>Larson, Maureen K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tiludronate concentrations and cytologic findings in synovial fluid after intravenous regional limb perfusion with tiludronate in horses</atitle><jtitle>PeerJ (San Francisco, CA)</jtitle><addtitle>PeerJ</addtitle><date>2015-04-28</date><risdate>2015</risdate><volume>3</volume><spage>e889</spage><epage>e889</epage><pages>e889-e889</pages><issn>2167-8359</issn><eissn>2167-8359</eissn><abstract>Anecdotal accounts of tiludronate administration via intravenous regional limb perfusion (IVRLP) exist despite a lack of information regarding safety for synovial structures in the perfused area. The objective of this study was to determine whether tiludronate concentrations in synovial structures after IVRLP with low dose (0.5 mg, LDT) or high dose (50 mg, HDT) tiludronate remain below a value demonstrated in vitro to be safe for articular cartilage (&lt;19,000 ng/ml), and to determine effects of tiludronate on synovial fluid cytology variables compared to saline perfused control limbs. Using a randomized controlled experimental study design, horses received IVRLP with LDT (n = 6) or HDT (n = 6) in one forelimb and IVRLP with saline in the contralateral limb. Synovial fluid cytology variables and tiludronate concentrations were evaluated in navicular bursae (NB), and distal interphalangeal (DIP) and metacarpophalangeal (MCP) joints one week before and 30-45 min after IVRLP, and in DIP and MCP joints 24 h after IVRLP. Data were analyzed with 2-way rmANOVA (p &lt; 0.05). Highest measured synovial fluid tiludronate concentrations occurred 30-45 min post-perfusion. Mean tiludronate concentrations were lower in LDT limbs (MCP = 39.6 ± 14.3 ng/ml, DIP = 118.1 ± 66.6 ng/ml, NB = 82.1 ± 30.2 ng/ml) than in HDT limbs (MCP = 3,745.1 ± 1,536.6 ng/ml, DIP = 16,274.0 ± 5,460.2 ng/ml, NB = 6,049.3 ± 1,931.7 ng/ml). Tiludronate concentration was &gt;19,000 ng/ml in DIP joints of two HDT limbs. Tiludronate was measurable only in synovial fluid from HDT limbs 24 h post-perfusion. There were no differences in synovial fluid cytology variables between control and treated limbs. Conclusions. In some horses, IVRLP with HDT may result in synovial fluid concentrations of tiludronate that may have adverse effects on articular cartilage, based on in vitro data. IVRLP with LDT is unlikely to promote articular cartilage degradation. Further studies to determine a safe and effective dose for IVRLP with tiludronate are needed.</abstract><cop>United States</cop><pub>PeerJ. Ltd</pub><pmid>25945303</pmid><doi>10.7717/peerj.889</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2167-8359
ispartof PeerJ (San Francisco, CA), 2015-04, Vol.3, p.e889-e889
issn 2167-8359
2167-8359
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_2d5a564c70e5490eab5d7588cd51a00b
source Open Access: PubMed Central; Publicly Available Content (ProQuest)
subjects Analysis
Arthritis
Bone disorder agents
Cartilage (articular)
Cellular biology
Cytology
Data processing
Disease
Drugs and Devices
Horse
Horses
Intravenous administration
Intravenous regional limb perfusion
Limbs
Orthopedics
Perfusion
Pharmacology
Synovial fluid
Tiludronate
Veins & arteries
Veterinary Medicine
title Tiludronate concentrations and cytologic findings in synovial fluid after intravenous regional limb perfusion with tiludronate in horses
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T12%3A00%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tiludronate%20concentrations%20and%20cytologic%20findings%20in%20synovial%20fluid%20after%20intravenous%20regional%20limb%20perfusion%20with%20tiludronate%20in%20horses&rft.jtitle=PeerJ%20(San%20Francisco,%20CA)&rft.au=Hunter,%20Barbara%20G&rft.date=2015-04-28&rft.volume=3&rft.spage=e889&rft.epage=e889&rft.pages=e889-e889&rft.issn=2167-8359&rft.eissn=2167-8359&rft_id=info:doi/10.7717/peerj.889&rft_dat=%3Cgale_doaj_%3EA543478006%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c637t-ee94f2a5906156ce884c3e4b9bcf24ab437a2a6264f70aca37f9f268952f9dbb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1957636826&rft_id=info:pmid/25945303&rft_galeid=A543478006&rfr_iscdi=true